71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES

EGFR-mutant lung adenocarcinomas (EGFRm-LUAD) have a higher risk of brain metastasis (BM) development than non-mutant lesions regardless of cancer stage. BM development is a marker of tumor aggressiveness and has significant prognostic impact that leads to treatment failure. MGMT promoter methylatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Mamatjan, Yasin, Zuccato, Jeffrey, Moraes, Fabio, Cabanero, Michael, Shali, Wumairehan, Weiss, Jessica, Tsao, Ming, Aldape, Kenneth, Shepherd, Frances, Zadeh, Gelareh
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Supplement Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7401348/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa073.058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados